2-carbomethoxy-8-(3-fluoropropyl)-3-(4-iodophenyl)tropane and Brain-Concussion

To determine whether there were differences in clinical outcomes for ioflupane I. We performed a case-control study among patients presenting to the Emergency Room (ER) during 2006-2013 with mTBI (cases, n = 34) or without mTBI (controls, n = 33). We performed clinical and imaging measurements in cases and controls at least 1-year post-presentation to the ER (average three years four months).. All DaTscans obtained were qualitatively normal. There were no qualitative DaTscan differences between cases and controls. There was, however, a significant increase in caudate asymmetry in controls versus cases (p = 0.02), but this finding was no longer significant after correction for multiple comparisons. There was a suggestion of a trend of poorer clinical score test measures among those with mTBI, although the overall mean score difference between cases and controls was not clinically significant.. Our small study does not provide support for DaTscan changes suggestive of PD in the one to seven years following mTBI. A trend towards poorer clinical measures was seen but was not clinically relevant in our small sample. Further work in a large population is necessary to support these findings.

Topics: Adolescent; Adult; Aged; Biomarkers; Brain; Brain Concussion; Case-Control Studies; Female; Humans; Male; Middle Aged; Nortropanes; Parkinson Disease; Tomography, Emission-Computed, Single-Photon; Young Adult